Skip to main content
Clinical Trials/ITMCTR2100004678
ITMCTR2100004678
Recruiting
Phase 4

A randomized double-blind controlled clinical study on the effects of qishen yiqi dropping pills on exercise endurance and quality of life in patients with coronary heart disease after interventional therapy

China-Japan Friendship Hospital0 sitesTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
China-Japan Friendship Hospital
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
China-Japan Friendship Hospital

Eligibility Criteria

Inclusion Criteria

  • 1\. Have a clear understanding of the research content and purpose, participate in the study voluntarily, and sign the informed consent form by himself / herself;
  • 2\. It is consistent with the diagnostic criteria of Western medicine for stable coronary heart disease;
  • 3\. Patients with Qi deficiency and blood stasis syndrome who meet the above diagnostic criteria of TCM;
  • 4\. Complete the overall treatment plan after PCI;
  • 5\. Within 1 week to 6 months after PCI;
  • 6\. The age is between 18 and 75 years old.

Exclusion Criteria

  • 1\. There are contraindications of cardiopulmonary exercise test;
  • 2\. Plan for coronary artery bypass grafting or heart transplantation;
  • 3\. Within 3 months before admission: stroke, transient ischemic attack; carotid artery or other major vascular surgery; persistent ventricular tachycardia or ventricular fibrillation;
  • 4\. Ventricular arrhythmia was not controlled effectively (antiarrhythmic drugs or implantable defibrillator were ineffective;
  • 5\. Uncorrected primary obstruction or severe reflux valvular disease, non dilated (restrictive) or hypertrophic cardiomyopathy;
  • 6\. Patients with second or third degree heart block or sick sinus syndrome, without permanent pacemaker, who need implantable devices for heart failure;
  • 7\. Obstructive or bronchospasmodic lung disease (such as asthma, bronchitis, etc.) requires oral or inhaled bronchodilator or hormone therapy;
  • 8\. Pregnant or lactating women and women who plan to become pregnant during the trial period;
  • 9\. Cancer or other systemic diseases, the expected survival time is less than 12 months;
  • 10\. Use other clinical trial drugs or participate in medical device test within 30 days before enrollment;

Outcomes

Primary Outcomes

Not specified

Similar Trials